Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    2
    ...
ATC Name B/G Ingredients Dosage Form Price
R06AX27 DESLAMED G Desloratadine - 0.5mg/ml 0.5mg/ml Solution 323,802 L.L
R06AX27 DESLOR CHAPHA G Desloratadine - 0.5mg/ml 0.5mg/ml Solution 323,802 L.L
R06AX27 DESLORATADINE ARROW G Desloratadine - 0.5mg/ml 0.5mg/ml Solution 256,674 L.L
R06AX DELINE CORT G Desloratadine - 5mg/5ml, Betamethasone - 0.25mg/5ml Syrup 693,679 L.L
R06AX DESLAMED FORTE G Desloratadine - 1mg/ml, Betamethasone - 0.05mg/ml Syrup 1,009,802 L.L
R06AX DESLAMED FORTE G Desloratadine - 1mg/ml, Betamethasone - 0.05mg/ml Syrup 673,201 L.L
R06AX DESLOCORT G Desloratadine - 1mg/ml, Betamethasone - 0.05mg/ml Syrup 1,009,802 L.L
R06AX DESLOCORT G Desloratadine - 1mg/ml, Betamethasone - 0.05mg/ml Syrup 673,201 L.L
R06AB54 DRAUDEX G Chlorphenamine maleate - 4mg, Phenylephrine - 5mg Tablet, sugar coated 166,381 L.L
R06AA02 DIPHENIST G Diphenhydramine HCl - 50mg/ml 50mg/ml Injectable solution 6,977,230 L.L
R05X DULSANA COUGH B Menthol - 0.25mg/5ml, Ammonium chloride - 100mg/5ml, Ephedrine HCl - 4mg/5ml, Carbinoxamine maleate - 2mg/5ml Syrup 223,974 L.L
R05X DULSANA MILD B Menthol - 0.125mg/5ml, Citric acid - 10mg/5ml, Sodium citrate - 20mg/5ml, Ammonium chloride - 50mg/5ml, Ephedrine HCl - 1.8mg/5ml, Carbinoxamine maleate - 1mg/5ml Syrup 216,295 L.L
R05DA09 DIACOL G Dextromethorphan HBr - 27mg/15ml 27mg/15ml Syrup 517,379 L.L
R05D DULSANA WITH CODEINE B Menthol - 0.25mg/5ml, Ammonium chloride - 100mg/5ml, Codeine phosphate - 10mg/5ml, Ephedrine HCl - 4mg/5ml, Carbinoxamine maleate - 2mg/5ml Syrup 273,888 L.L
R05CB10 DILAMUC G Dried Ivy leaf extract - 170mg/100ml, Glycyrrhizic acid (Glycyrrhiza Glabra, Liquorice root) - 164mg/100ml, Thyme - 760mg/100ml Syrup 456,906 L.L
R03AL02 DUOLIN RESPULES G Salbutamol (sulfate) - 2.5mg/2.5ml, Ipratropium bromide (monohydrate) - 500mcg/2.5ml Inhaltion solution with nebuliser 417,935 L.L
R01AD58 DYMISTA B Fluticasone propionate - 50mcg/actuation, Azelastine HCl - 137mcg/actuation Spray, suspension 2,183,744 L.L
R01AA07 DECOZAL G Xylometazoline HCl - 0.1% 0.1% Metered dose spray 147,823 L.L
R01AA07 DECOZAL G Xylometazoline HCl - 0.1% 0.1% Drops 145,135 L.L
R01AA07 DECOZAL G Xylometazoline HCl - 0.05% 0.05% Metered dose spray 155,886 L.L
R01AA07 DECOZAL G Xylometazoline HCl - 0.05% 0.05% Metered dose spray 108,851 L.L
P01BA02 DOLQUINE G Hydroxychloroquine sulfate - 200mg 200mg Tablet, coated 1,191,988 L.L
N06DA02 DONECEPT 5 G Donepezil HCl - 5mg 5mg Tablet, film coated 1,970,969 L.L
N06DA02 DONEPEZIL ARROW G Donepezil HCl - 5mg 5mg Tablet, film coated 1,365,344 L.L
N06DA02 DONEPEZIL BIOGARAN G Donepezil HCl - 5mg 5mg Tablet, coated 1,325,029 L.L
N06DA02 DOPEZIL G Donepezil HCl - 5mg 5mg Tablet, film coated 1,034,759 L.L
N06DA02 DONECEPT 10 G Donepezil HCl - 10mg 10mg Tablet, film coated 2,292,595 L.L
N06DA02 DONEPEZIL ARROW G Donepezil HCl - 10mg 10mg Tablet, film coated 1,365,344 L.L
N06DA02 DONEPEZIL BIOGARAN G Donepezil HCl - 10mg 10mg Tablet, coated 1,325,029 L.L
N06DA02 DOPEZIL G Donepezil HCl - 10mg 10mg Tablet, film coated 1,381,470 L.L
    2
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025